◇
Brand Creation
- How should a pharmaceutical company create a defensible product name?
- House mark or product mark - which deserves priority?
- When does a common pharmaceutical prefix weaken a brand?
Pharma Brand Intelligence
Better Brand Decisions Begin With Better Questions.
Pharma Brand Intelligence is TM Assist's knowledge platform for the trademark and commercial issues surrounding pharmaceutical brands.
Not generic legal updates.Practical thinking for the people who create, manufacture, market, own, distribute and acquire pharmaceutical brands.
Brand CreationSearch & ClearanceOwnershipPortfolioInternationalTransactionsEnforcement
⌕
Search & Clearance
- Why does "no exact match" not mean "safe to use"?
- When can differently spelled medicine names still be too close?
- How should a company compare shortlisted pharmaceutical names?
◈
Ownership
- Who should own the brand in a third-party manufacturing arrangement?
- Can a PCD partner claim rights over the product name?
- What happens when a distributor registers the brand abroad?
▦
Portfolio
- What does a pharmaceutical trademark portfolio audit reveal?
- When should unused brands be retained?
- How should house marks and product marks be organised?
◎
International
- When should an exporter clear its trademark overseas?
- Madrid Protocol or direct filing?
- What trademark provisions belong in an overseas distribution agreement?
⇄
Transactions
- What should be checked before acquiring a pharmaceutical brand?
- Does the seller actually own the trademark being sold?
- How should trademark rights move in a business acquisition?
Protect What You Build
Enforcement
- When should a pharmaceutical company oppose a similar mark?
- When is enforcement commercially worthwhile?
- Can coexistence sometimes be better than litigation?
Pharma Brand Intelligence